JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors

Emily A. Irey, Chelsea M. Lassiter, Nicholas J. Brady, Polly Chuntova, Ying Wang, Todd P Knutson, Christy Henzler, Thomas S. Chaffee, Rachel I Vogel, Andrew C Nelson, Michael A Farrar, Kaylee Schwertfeger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tumor-associated macrophages contribute to tumor progression and therapeutic resistance in breast cancer. Within the tumor microenvironment, tumor-derived factors activate pathways that modulate macrophage function. Using in vitro and in vivo models, we find that tumor-derived factors induce activation of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway in macrophages. We also demonstrate that loss of STAT3 in myeloid cells leads to enhanced mammary tumorigenesis. Further studies show that macrophages contribute to resistance of mammary tumors to the JAK/STAT inhibitor ruxolitinib in vivo and that ruxolitinib-treated macrophages produce soluble factors that promote resistance of tumor cells to JAK inhibition in vitro. Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib. These findings define a mechanism through which macrophages promote therapeutic resistance and highlight the importance of understanding the impact of targeted therapies on the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)12442-12451
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number25
DOIs
StatePublished - Jun 18 2019

Fingerprint

Janus Kinases
Macrophages
STAT3 Transcription Factor
Neoplasms
Tumor Microenvironment
Cyclooxygenase 2
Therapeutics
Breast Neoplasms
R Factors
Myeloid Cells
Carcinogenesis
Breast

Keywords

  • Breast cancer
  • Inflammation
  • JAK
  • Mammary tumor
  • STAT

PubMed: MeSH publication types

  • Journal Article

Cite this

JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. / Irey, Emily A.; Lassiter, Chelsea M.; Brady, Nicholas J.; Chuntova, Polly; Wang, Ying; Knutson, Todd P; Henzler, Christy; Chaffee, Thomas S.; Vogel, Rachel I; Nelson, Andrew C; Farrar, Michael A; Schwertfeger, Kaylee.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 25, 18.06.2019, p. 12442-12451.

Research output: Contribution to journalArticle

@article{4bd6943ed8524e4595da5957ef0ea29c,
title = "JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors",
abstract = "Tumor-associated macrophages contribute to tumor progression and therapeutic resistance in breast cancer. Within the tumor microenvironment, tumor-derived factors activate pathways that modulate macrophage function. Using in vitro and in vivo models, we find that tumor-derived factors induce activation of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway in macrophages. We also demonstrate that loss of STAT3 in myeloid cells leads to enhanced mammary tumorigenesis. Further studies show that macrophages contribute to resistance of mammary tumors to the JAK/STAT inhibitor ruxolitinib in vivo and that ruxolitinib-treated macrophages produce soluble factors that promote resistance of tumor cells to JAK inhibition in vitro. Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib. These findings define a mechanism through which macrophages promote therapeutic resistance and highlight the importance of understanding the impact of targeted therapies on the tumor microenvironment.",
keywords = "Breast cancer, Inflammation, JAK, Mammary tumor, STAT",
author = "Irey, {Emily A.} and Lassiter, {Chelsea M.} and Brady, {Nicholas J.} and Polly Chuntova and Ying Wang and Knutson, {Todd P} and Christy Henzler and Chaffee, {Thomas S.} and Vogel, {Rachel I} and Nelson, {Andrew C} and Farrar, {Michael A} and Kaylee Schwertfeger",
year = "2019",
month = "6",
day = "18",
doi = "10.1073/pnas.1816410116",
language = "English (US)",
volume = "116",
pages = "12442--12451",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "25",

}

TY - JOUR

T1 - JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors

AU - Irey, Emily A.

AU - Lassiter, Chelsea M.

AU - Brady, Nicholas J.

AU - Chuntova, Polly

AU - Wang, Ying

AU - Knutson, Todd P

AU - Henzler, Christy

AU - Chaffee, Thomas S.

AU - Vogel, Rachel I

AU - Nelson, Andrew C

AU - Farrar, Michael A

AU - Schwertfeger, Kaylee

PY - 2019/6/18

Y1 - 2019/6/18

N2 - Tumor-associated macrophages contribute to tumor progression and therapeutic resistance in breast cancer. Within the tumor microenvironment, tumor-derived factors activate pathways that modulate macrophage function. Using in vitro and in vivo models, we find that tumor-derived factors induce activation of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway in macrophages. We also demonstrate that loss of STAT3 in myeloid cells leads to enhanced mammary tumorigenesis. Further studies show that macrophages contribute to resistance of mammary tumors to the JAK/STAT inhibitor ruxolitinib in vivo and that ruxolitinib-treated macrophages produce soluble factors that promote resistance of tumor cells to JAK inhibition in vitro. Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib. These findings define a mechanism through which macrophages promote therapeutic resistance and highlight the importance of understanding the impact of targeted therapies on the tumor microenvironment.

AB - Tumor-associated macrophages contribute to tumor progression and therapeutic resistance in breast cancer. Within the tumor microenvironment, tumor-derived factors activate pathways that modulate macrophage function. Using in vitro and in vivo models, we find that tumor-derived factors induce activation of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway in macrophages. We also demonstrate that loss of STAT3 in myeloid cells leads to enhanced mammary tumorigenesis. Further studies show that macrophages contribute to resistance of mammary tumors to the JAK/STAT inhibitor ruxolitinib in vivo and that ruxolitinib-treated macrophages produce soluble factors that promote resistance of tumor cells to JAK inhibition in vitro. Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib. These findings define a mechanism through which macrophages promote therapeutic resistance and highlight the importance of understanding the impact of targeted therapies on the tumor microenvironment.

KW - Breast cancer

KW - Inflammation

KW - JAK

KW - Mammary tumor

KW - STAT

UR - http://www.scopus.com/inward/record.url?scp=85067596818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067596818&partnerID=8YFLogxK

U2 - 10.1073/pnas.1816410116

DO - 10.1073/pnas.1816410116

M3 - Article

C2 - 31147469

AN - SCOPUS:85067596818

VL - 116

SP - 12442

EP - 12451

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 25

ER -